David Llewellyn (L) and Joe Illingworth, DJS Antibodies co-founders
October 20, 2022 10:45 AM EDT
Deals

Ab­b­Vie re­cruits a GPCR team in Ox­ford, buy­ing out a fledg­ling biotech for $255M+

John Carroll

Editor & Founder

Less than 2 years af­ter some Ox­ford grads pieced to­geth­er a lit­tle £6 mil­lion seed fund to launch their dis­cov­ery out­fit, the an­ti­body de­vel­op­er has …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times